Hexiang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hexiang Chen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Chunchun Zhai
Renmin Hospital of Wuhan University
3 shared publicationsCheng Xu
Department of Anesthesiology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China
2 shared publicationsLihua Yao
Department of Psychiatry, Renmin Hospital of Wuhan University, 430060 Wuhan, Hubei, China
2 shared publicationsQingjian Liu
Department of Anesthesiology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China
2 shared publicationsShaoqun Tang
Department of Anesthesiology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China
2 shared publicationsWei Wang
Department of Psychiatry, Renmin Hospital of Wuhan University, 430060 Wuhan, Hubei, China
2 shared publications
Latest Publications
- Open Access
- 9 April 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (2)
The Association Between Serum Vitamin D and Lipid Levels in Patients With Depression: A Cross-Sectional Study
Background: Vitamin D deficiency is prevalent among individuals with depression; however, clinical findings regarding this association have been inconsistent. Additionally, a significant proportion of depressed patients present with dyslipidemia, yet the interplay between vitamin D status, lipid metabolism, and depression remains poorly understood. We aimed to explore the role of vitamin D in depression and to investigate the potential associations between vitamin D status, lipid metabolism, and depressive symptoms. Methods: We recruited 412 first-episode, drug-naïve patients with depression and 180 age-matched healthy controls. Fasting venous blood samples were collected in the morning to quantify serum vitamin D and lipid profiles. Depressive symptoms were assessed on the day of blood collection using both the Patient Health Questionnaire-9 (PHQ-9) and the 17-item Hamilton Depression Rating Scale (HAMD-17). Spearman's rank correlation was employed to examine associations between serum vitamin D concentrations and depressive symptom severity. Binary logistic regression analysis was subsequently performed to identify potential risk factors for depression. Results: Compared with healthy controls, depressed patients had significantly lower serum vitamin D and high-density lipoprotein cholesterol (HDL-C) levels. This sex-specific pattern showed that male patients had lower vitamin D, while female patients had lower HDL-C. Spearman's correlation analysis revealed significant inverse correlations of vitamin D and triglyceride (TG) with PHQ-9 and HAMD-17 scores among depressed patients. Logistic regression analysis indicated that individuals with higher vitamin D levels had a reduced likelihood of depression compared with those with low vitamin D levels (adjusted odds ratio (OR) = 0.950, 95% confidence interval (CI): 0.920–0.982, p = 0.002). Similarly, subjects with elevated HDL-C levels were associated with a lower likelihood of depression relative to those with diminished HDL-C levels (adjusted OR = 0.317, 95% CI: 0.173–0.583, p < 0.001). Conclusion: Serum vitamin D and HDL-C levels were lower in patients with depression than in healthy individuals. Both vitamin D and HDL-C may be inversely associated with depression.
- 9 April 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (2)
Open AccessThe Association Between Serum Vitamin D and Lipid Levels in Patients With Depression: A Cross-Sectional Study
Background: Vitamin D deficiency is prevalent among individuals with depression; however, clinical findings regarding this association have been inconsistent. Additionally, a significant proportion of depressed patients present with dyslipidemia, yet the interplay between vitamin D status, lipid metabolism, and depression remains poorly understood. We aimed to explore the role of vitamin D in depression and to investigate the potential associations between vitamin D status, lipid metabolism, and depressive symptoms. Methods: We recruited 412 first-episode, drug-naïve patients with depression and 180 age-matched healthy controls. Fasting venous blood samples were collected in the morning to quantify serum vitamin D and lipid profiles. Depressive symptoms were assessed on the day of blood collection using both the Patient Health Questionnaire-9 (PHQ-9) and the 17-item Hamilton Depression Rating Scale (HAMD-17). Spearman's rank correlation was employed to examine associations between serum vitamin D concentrations and depressive symptom severity. Binary logistic regression analysis was subsequently performed to identify potential risk factors for depression. Results: Compared with healthy controls, depressed patients had significantly lower serum vitamin D and high-density lipoprotein cholesterol (HDL-C) levels. This sex-specific pattern showed that male patients had lower vitamin D, while female patients had lower HDL-C. Spearman's correlation analysis revealed significant inverse correlations of vitamin D and triglyceride (TG) with PHQ-9 and HAMD-17 scores among depressed patients. Logistic regression analysis indicated that individuals with higher vitamin D levels had a reduced likelihood of depression compared with those with low vitamin D levels (adjusted odds ratio (OR) = 0.950, 95% confidence interval (CI): 0.920–0.982, p = 0.002). Similarly, subjects with elevated HDL-C levels were associated with a lower likelihood of depression relative to those with diminished HDL-C levels (adjusted OR = 0.317, 95% CI: 0.173–0.583, p < 0.001). Conclusion: Serum vitamin D and HDL-C levels were lower in patients with depression than in healthy individuals. Both vitamin D and HDL-C may be inversely associated with depression.
- Open Access
- 24 October 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (11) , 1501
The Mediation Role of Sleep Disturbances between Vitamin D and Depressive Symptoms: A Cross-Sectional Study
Depression and sleep disturbances are highly prevalent health problems that have been suggested to be associated with vitamin D deficiency. This study investigated whether sleep disturbances affect the association between vitamin D and depressive symptoms. A total of 425 patients with depression were included in this study. Spearman correlation coefficients were chosen to assess the relation between vitamin D concentrations and depressive symptomatology (according to the PHQ-9 and HAMD-17 scores). The GLM Mediation Model in the Medmod module for data analysis in Jamovi 2.2.5 was used to analyze the mediation models for sleep disturbances. Vitamin D concentrations were significantly correlated with PHQ-9 and HAMD-17 scale scores. In addition, item 3 was suggested to have a mediating effect between vitamin D and depressive symptoms in the mediating model of PHQ-9, and item 4 was suggested to have a mediating effect between vitamin D and depressive symptoms in the mediating model of HAMD-17. Sleep disturbances (especially difficulty falling asleep) are mediators between vitamin D and depressive symptoms, suggesting that increasing vitamin D levels at the right time to regulate sleep disturbances may improve depression symptoms, yet further research is necessary.
- 24 October 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (11) , 1501
Open AccessThe Mediation Role of Sleep Disturbances between Vitamin D and Depressive Symptoms: A Cross-Sectional Study
Depression and sleep disturbances are highly prevalent health problems that have been suggested to be associated with vitamin D deficiency. This study investigated whether sleep disturbances affect the association between vitamin D and depressive symptoms. A total of 425 patients with depression were included in this study. Spearman correlation coefficients were chosen to assess the relation between vitamin D concentrations and depressive symptomatology (according to the PHQ-9 and HAMD-17 scores). The GLM Mediation Model in the Medmod module for data analysis in Jamovi 2.2.5 was used to analyze the mediation models for sleep disturbances. Vitamin D concentrations were significantly correlated with PHQ-9 and HAMD-17 scale scores. In addition, item 3 was suggested to have a mediating effect between vitamin D and depressive symptoms in the mediating model of PHQ-9, and item 4 was suggested to have a mediating effect between vitamin D and depressive symptoms in the mediating model of HAMD-17. Sleep disturbances (especially difficulty falling asleep) are mediators between vitamin D and depressive symptoms, suggesting that increasing vitamin D levels at the right time to regulate sleep disturbances may improve depression symptoms, yet further research is necessary.
- Open Access
- 18 December 2020
- Published by Springer Nature in Research Square
Ultrasound-guided Parasternal Intercostal Nerve Block for Postoperative Analgesia in Mediastinal Mass Resection by Median Sternotomy: a Randomized, Double-blind, Placebo-controlled Trial
Background: Ultrasound-guided parasternal intercostal nerve block is rarely used for postoperative analgesia, and its value remains unclear. This study aimed to evaluate the effectiveness of ultrasound-guided parasternal intercostal nerve block for postoperative analgesia in patients undergoing median sternotomy for mediastinal mass resection.Methods: This randomized, double-blind, placebo-controlled trial performed in Renmin Hospital, Wuhan University, enrolled 41 participants aged 18-65 years. The patients scheduled for mediastinal mass resection by median sternotomy were randomly assigned were randomized into 2 groups, and preoperatively administered 2 injections of ropivacaine (PSI) and saline (control) groups, respectively, in the 3rd and 5th parasternal intercostal spaces with ultrasound-guided (USG) bilateral parasternal intercostal nerve block. Sufentanil via patient-controlled intravenous analgesia (PCIA) was administered to all participants postoperatively. Pain score, total sufentanil consumption, and postoperative adverse events were recorded within the first 24 hours.Results: There were 20 and 21 patients in the PSI and control group, respectively. The PSI group required 20% less PCIA-sufentanil compared with the control group (54.05 ± 11.14 μg vs. 67.67 ± 8.92 μg; P < 0.001). In addition, pain numerical rating scale (NRS) scores were significantly lower in the PSI group compared with control patients, both at rest and upon coughing within 24 postoperative hours. Postoperative adverse events were generally reduced in the PSI group compared with controls. Conclusions: USG bilateral parasternal intercostal nerve block effectively reduces postoperative pain and adjuvant analgesic requirement, with good patient satisfaction, therefore constituting a good option for mediastinal mass resection by median sternotomy.
- 18 December 2020
- Published by Springer Nature in Research Square
Open AccessUltrasound-guided Parasternal Intercostal Nerve Block for Postoperative Analgesia in Mediastinal Mass Resection by Median Sternotomy: a Randomized, Double-blind, Placebo-controlled Trial
Background: Ultrasound-guided parasternal intercostal nerve block is rarely used for postoperative analgesia, and its value remains unclear. This study aimed to evaluate the effectiveness of ultrasound-guided parasternal intercostal nerve block for postoperative analgesia in patients undergoing median sternotomy for mediastinal mass resection.Methods: This randomized, double-blind, placebo-controlled trial performed in Renmin Hospital, Wuhan University, enrolled 41 participants aged 18-65 years. The patients scheduled for mediastinal mass resection by median sternotomy were randomly assigned were randomized into 2 groups, and preoperatively administered 2 injections of ropivacaine (PSI) and saline (control) groups, respectively, in the 3rd and 5th parasternal intercostal spaces with ultrasound-guided (USG) bilateral parasternal intercostal nerve block. Sufentanil via patient-controlled intravenous analgesia (PCIA) was administered to all participants postoperatively. Pain score, total sufentanil consumption, and postoperative adverse events were recorded within the first 24 hours.Results: There were 20 and 21 patients in the PSI and control group, respectively. The PSI group required 20% less PCIA-sufentanil compared with the control group (54.05 ± 11.14 μg vs. 67.67 ± 8.92 μg; P < 0.001). In addition, pain numerical rating scale (NRS) scores were significantly lower in the PSI group compared with control patients, both at rest and upon coughing within 24 postoperative hours. Postoperative adverse events were generally reduced in the PSI group compared with controls. Conclusions: USG bilateral parasternal intercostal nerve block effectively reduces postoperative pain and adjuvant analgesic requirement, with good patient satisfaction, therefore constituting a good option for mediastinal mass resection by median sternotomy.
- Open Access
- 30 October 2020
- Published by Wiley in Mediators of Inflammation
- Vol. 2020, 1-3
Corrigendum to “Interleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice”
In the article titled “Interleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice” [1], the authors apologize that a blot of P-STAT3 which did not belong to this study was mistakenly used in (Figure 6(c)). The statistical results of P-STAT3 protein expression were correct, and the corrected (Figure 6(c)) is shown below.
- 30 October 2020
- Published by Wiley in Mediators of Inflammation
- Vol. 2020, 1-3
Open AccessCorrigendum to “Interleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice”
In the article titled “Interleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice” [1], the authors apologize that a blot of P-STAT3 which did not belong to this study was mistakenly used in (Figure 6(c)). The statistical results of P-STAT3 protein expression were correct, and the corrected (Figure 6(c)) is shown below.
- Open Access
- 14 February 2020
- Published by Wiley in Mediators of Inflammation
- Vol. 2020, 1-12
Interleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice
Background. Multiple interleukin (IL) family members were reported to be closely related to hypertension. We aimed to investigate whether IL-9 affects angiotensin II- (Ang II-) induced hypertension in mice. Methods. Mice were treated with Ang II, and IL-9 expression was determined. In addition, effects of IL-9 knockout (KO) on blood pressure were observed in Ang II-infused mice. To determine whether the effects of IL-9 on blood pressure was mediated by the signal transducer and activator of the transcription 3 (STAT3) pathway, Ang II-treated mice were given S31-201. Furthermore, circulating IL-9 levels in patients with hypertension were measured. Results. Ang II treatment increased serum and aortic IL-9 expression in a dose-dependent manner; IL-9 levels were the highest in the second week and continued to remain high into the fourth week after the treatment. IL-9 KO downregulated proinflammatory cytokine expression, whereas it upregulated anti-inflammatory cytokine levels, relieved vascular dysfunction, and decreased blood pressure in Ang II-infused mice. IL-9 also reduced smooth muscle 22α (SM22α) expression and increased osteopontin (OPN) levels both in mice and in vitro. The effects of IL-9 KO on blood pressure and inflammatory response were significantly reduced by S31-201 treatment. Circulating IL-9 levels were significantly increased in patients with the hypertension group than in the control group, and elevated IL-9 levels positively correlated with both systolic blood pressure and diastolic blood pressure in patients with hypertension. Conclusions. IL-9 KO alleviates inflammatory response, prevents phenotypic transformation of smooth muscle, reduces vascular dysfunction, and lowers blood pressure via the STAT3 pathway in Ang II-infused mice. IL-9 might be a novel target for the treatment and prevention of clinical hypertension.
- 14 February 2020
- Published by Wiley in Mediators of Inflammation
- Vol. 2020, 1-12
Open AccessInterleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice
Background. Multiple interleukin (IL) family members were reported to be closely related to hypertension. We aimed to investigate whether IL-9 affects angiotensin II- (Ang II-) induced hypertension in mice. Methods. Mice were treated with Ang II, and IL-9 expression was determined. In addition, effects of IL-9 knockout (KO) on blood pressure were observed in Ang II-infused mice. To determine whether the effects of IL-9 on blood pressure was mediated by the signal transducer and activator of the transcription 3 (STAT3) pathway, Ang II-treated mice were given S31-201. Furthermore, circulating IL-9 levels in patients with hypertension were measured. Results. Ang II treatment increased serum and aortic IL-9 expression in a dose-dependent manner; IL-9 levels were the highest in the second week and continued to remain high into the fourth week after the treatment. IL-9 KO downregulated proinflammatory cytokine expression, whereas it upregulated anti-inflammatory cytokine levels, relieved vascular dysfunction, and decreased blood pressure in Ang II-infused mice. IL-9 also reduced smooth muscle 22α (SM22α) expression and increased osteopontin (OPN) levels both in mice and in vitro. The effects of IL-9 KO on blood pressure and inflammatory response were significantly reduced by S31-201 treatment. Circulating IL-9 levels were significantly increased in patients with the hypertension group than in the control group, and elevated IL-9 levels positively correlated with both systolic blood pressure and diastolic blood pressure in patients with hypertension. Conclusions. IL-9 KO alleviates inflammatory response, prevents phenotypic transformation of smooth muscle, reduces vascular dysfunction, and lowers blood pressure via the STAT3 pathway in Ang II-infused mice. IL-9 might be a novel target for the treatment and prevention of clinical hypertension.